Background and Objectives: Loss to follow-up is a common problem of most patients on antiretroviral therapy in Ethiopia. Second-line antiretroviral therapy is the drug that would be used when the first-line therapy fails. Thus this study intends to determine the incidence and risk factors of time to losses to follow up among Human Immunodeficiency Virus (HIV) patients on second line regimens of Antiretroviral Therapy(ART) in Amhara region Hospitals, Ethiopia. Methods: Institutional based retrospective cohort study was conducted in the Amhara region hospitals from February to March 2016. A total of 1246 patient from eight hospitals in Amhara region were selected using simple random sampling method and data were extracted from patient charts. The log rank test was used to assess presence of significant difference in time to losses to follow among levels of categorical variables. Both bi-variiable and multivariable Cox proportional hazards models were used to identify factors that affect the time to losses to follow up. Results: The cumulative incidence of loss to follow up was 5.41% over the entire (eight) years of follow-up. The cumulative incidence rates of death and transfer out were 10.99% and 10.02 %, respectively. In multivariable Cox regression analysis, ambulatory functional status (AHR=0.1967, 95% CI: 0.049-0 .794), male gender (AHR=2.135, 95% CI: 1.053-4.330), and adherence to ART (AHR=0.442, 95% CI: 0.198-0.989) were significant predictors of time to losses to follow up. The use of 2a, 2e and 2g types of second line regimen reduced the risk of loss to follow up. Interpretations and Conclusions: The incidence of loss to follow up in Amhara region hospitals was low. Loss to folow up was negatively associated with female gender, ambulatory baseline functional status, adherence, and types of second line regimen types. Further research on the effect of types of drug is recommended by acertaining whether the reduction in loss to follow up for patients who took drug types of 2a, 2e, and 2g is associaed with improved or worsened health outcomes by trafcking lost patients closely.
INTRODUCTION
Since its introduction, Antiretroviral therapy (ART) has transformed the responses and emphasis that countries gave to HIV/AIDS and resulted in an improvement of health 1 . It has also brought a remarkable reduction in the transmission of HIV and HIV-related morbidity and mortality worldwide 2 .
At the end of 2012, 10 million more people were receiving ART in low-and middle-income countries 3 . In 2015, about 65% (15 million) of the total number of people living with the virus worldwide were receiving treatment for the HIV/AIDS 3 . However, even though there has been a continually increasing access to ART, still there are disparities across regions or countries.
When the first-line antiretroviral therapy fails, HIV patient would be recommended to take the second-line therapy 4 . It has been shown that patients loss to follow-up (LTFU) affects the quality of care that patients could get. Loss to follow up is defined as not taking ART refill for a period of 3 months or longer from the last attendance for refill and not yet classified as 'dead' or 'transferred-out' in second line regimens ART.It also affects the evaluation of ART programmes in developing countries 5 . A systematic review done in sub-Saharan Africa about ART programmes showed that the cumulative incidences of loss to follow-up of patients were 19%, 24% and 31% at 6, 12, and 24 months since the initiation of their treatment, respectively 5 .
Many studies conducted in many parts of the world indicate different results regarding the risk factors of loss to follow up (LTFU). A study done in India showed that the incidence of LTFU is 15.5% 6 . A study conducted in Sub-Saharan African showed that the incidence loss to follow up is 17.7% 7 . The incidences of lost follow-up in ART were 15.6%, 27%, and 36.6% for studies done in southeastern Nigeria 8 , South Africa 9 , and Cameron 10 , respectively. Studies done in Ethiopia showed that, the incidence of LTFU were 21.7%, 14.5%, 19.6% in southern Ethiopia hospitals 11 , Hadiya zone (Southern Nations, Nationalities and Peoples Region) 12 , and Ethiopian public hospital clinics 13 , respectively.
In Ethiopia, one of the major problems in ART programme is loss to follow up. A study done in southern Ethiopia 11 , Rural Ethiopia hospitals 14 , and Ethiopian public hospital clinics 13 showed that the incidence LTFU were 21.7%, 28.4%, and 19.6%, respectively.
A lot of factors were found to be associated with time-to-LTFU including socio demographic factors like educational status, sex, Age, occupational 6, 10, 14, [16] [17] [18] and clinical characteristics like Weight, Height, measures of number of T helper cells ( CD4 )count, hemoglobin level, Adherence, WHO stage, Functional status, second line regimen drug, Cotrimoxazole preventive therapy, Opportunistic infections, Body mass index 6, 7, [9] [10] [11] 17 . Functional status of a patient was categorized as "working" if their daily activities were not altered due to illness, "ambulatory" if the patient was not fully working but was able to do minor tasks at home, and "bed ridden" when the patient remained in bed most of the time.
A better understanding of the risk factors associated with loss to follow up in Ethiopia could be helpful to design interventions to reduce LTFU in patients who initiate ART. While evidences have proven that ART improves the survival time and quality of life of HIV patients, several clinical characteristics and socio demographic factors contributing to this high loss to follow up are not well understood in Ethiopia.
However, research studies investigating predictors of loss to follow up after ART initiations are scarce in Amhara Region. A better understanding of the risk factors associated with loss to follow up in the region could be helpful to design interventions to reduce Loss to Follow Up in patients who initiate ART. 
MATERIALS AND METHODS

Study design and setting
Sample size determination
The sample size for the first objective was calculated by using a single population proportion formula and taking the assumptions of 95% confidence level, margin of error as 5%, incidence of loss to follow up 19.6% which was taken from a study done in Ethiopian public hospital clinic 13 , and a design effect of 2. Finally, we have got a sample size of 484 persons on second line ART.
The sample size for the second objective was calculated by using double population proportion for survival analysis as:
Where P1 is the proportion of CD4 count greater than or equal to >=100 (60.3%) P2 the proportion of CD4 count Less than <100 (37.8%) ; d is that probability of observing the event (19.6%) ; b=2.36 is logarithm of hazard ratio square Hazard ratio of CD4 count <100 is 2.36 when CD4 count >=100 is as reference
Sampling procedure
Eight hospitals were selected using simple random sampling from 17 hospitals found in the Amhara region. ART data of HIV patients who initiated the treatment since February 2008 to February 2016 were retrospectively followed. Because, the maximum sample size determined is closer to the total number of ART in the eight Hospitals, we had taken all patients initiated the second line treatment in the specified period and hospitals ( Figure 1 
Data collection procedure and quality control
Data were extracted from standard medical registration books that were already recorded routinely by the data clerk at each hospital. These records were adopted by the National Center for AIDS and STD Control and Ministry of Health and were available at the ART centers. The data were collected by experienced ART programme who were trained on comprehensive HIV care and who were working in the ART clinic at selected hospitals. A supervisor was supervising the process of data collection.
To ensure the quality of data, data collectors who were clinical nurses by profession and were working in ART programs were selected. Moreover, about 5% of questionnaires were pre-tested seven days before the actual data collection was started. During data collection, close supervision was conducted by supervisors and principal investigator, by observing how the data collectors run and the collected data was checked for the completeness, accuracy and clarity. This quality checking was done daily after data collection and correction was made before the next data collection measure. Data clean up and crosschecking was done before analysis. After data collection, data was stored in a secured place to maintain confidentiality and backup of the data was stored in different areas not to lose the data. Each questionnaire was coded separately before analysis.
Data processing and analysis
All returned questionnaires were checked for completeness and consistency of responses visually. The collected data were coded and entered in to EPI INFO version 7 and exported to STATA (version 12) statistical software. Data were cleaned and analyzed using STATA version 12. During descriptive analysis, continuous variables were summarized using mean, median and standard deviation while categorical variables were summarized using proportions and then presented in tables and graphs. Bi-variable analyses were done to test for associations between the dependent variable (loss to follow up) and independent variables. Before inclusion of predictors to multivariable Cox regression analysis, fulfillment of model assumption was checked using goodness -of-fit test or Schoenfeld residuals (phtest). Multi co-linearity was checked using Variance Inflation Factors (VIF) or tolerance of explanatory variables. Survival analysis using life table and Kaplan-Meier survival curve were used to assess survival status of loss to follow up. The log rank test was used to assess presence of significant difference in survival status of loss to follow up between categorical socio demographic and clinical characteristics. Cox regression model was employed to measure the effect of each variable on the hazard of loss to follow up after adjusting for other variables at 95% confidence level. A variable with P-value < 0.05 in multivariable Cox regression analysis was considered as a factor associated with the loss to follow up at 95% confidence level.
Ethical Consideration
This study was approved by the ethical review committee of University of Gondar. Permission was obtained from the all the eight hospitals and the names of patients were not recoreded in our data extraction form and their unique ART numbers were kept locked for better confidentiality.
RESULTS
Socio-demographic characteristics
A total of 1246 adult HIV/AIDS patients participated in the study. The mean age of participants (mean [±SD]) was 32.98 (±.8.739) years, ranging from 15 to 73 years. Fifty one percent of patients were males, half belonged to less than 32 years of age, one third of them had attended secondary education, and more than one third were unemployed. One third patients were from Felege Hiwot referral hospital ( 
Baseline Clinical Characteristics
Seven hundred thirty eight (63%) of patients had history of past opportunistic infection; around 666 (55.5%) of the participants have CD4 cell count less than 100 cells/ml at baseline. About 638 (52.7%) of the patients were under WHO stage III. About 391 (41%) of patients were having poor adherence and majority (33.39%) of participate take drug type of 2g=TDF-3TC-LPV/r ( Table 2) .
Incidence of lost to follow-up
The study participants were assessed retrospectively with a total follow up of 38,956.7 person-months. The overall incidence density of loss to follow up was 1.67 losses to follow up per 1000 persons-months. The cumulative incidence of losses to follow up was 5.41% over the entire period of follow-up. Others cumulative incidences like death and transfers out were 10.99% and 10.02 %, respectively. The remaining 73.59 % of the participants were actively on treatment when the study ended.
Those who took CPT (blue line) and those who did not take it (red line) were statistically significantly different (p-value = 0.0319) with regard to the incidence of loss to follow up. The graph also showed a constantly diverging patter except at the end of the follow up period where less emphasis would be given due to the smaller sample size (Figure 2 ). .794). Those who have good adherence decreased the hazard of loss to follow up by 55.8 % as compared to those having poor adherence (AHR=0.442, 95% CI 0.198-0.989). Patients who took drug type 2a=ABC-DDI-LPV/r (Abacavirdidanosine-Lopinavir/ritonavir)decreased the hazard of loss to follow up by 93.9 % as compared to those who took drug type 2k=ABC-DDI-ATV/r(Atazanovir/ritonavir) (AHR=0.061, 95% CI 0.006-0.594). Those who took drug type 2e=AZT-3TC-LPV/r decreased the hazard of loss to follow up by 93.5 % as compared to those who took 2k=ABC-DDI-ATV/r (AHR= 0.065, 95% CI 0.005-0.825) ( Table 3) . 
DISCUSSION
In this study, the cumulative incidence rate of LTFU in ART care was 65 (5.41 %). This finding is lower than findings in India 6, SSA 7 , Nigeria 8 , South Africa 9 , and Cameron 10 . It is also lower than studies done in southern Ethiopia hospitals 11 , Hadiya zone 12 , and Ethiopian public hospital clinics 13 The differences could be due to variations in study design and patient time follow-ups. However, another study comprising different regions including SSA, Asia, Latin America and Eastern Europe 15 had got comparable finding with the current study. Regarding factors, male gender was a positive significant predictor for losses to follow up and good adherence, ambulatory functional status, and second line regimen drug types of 2a. 2e and 2g had an inverse association with the hazard of LTFU. In the current study, the hazard of loss to follow among males was 2.1 times higher as compared to females (AHR = 2.135, 95% CI 1.053-4.330). A similar finding was reported by a study conducted in India 6 , Cameron 10 and north Ethiopia 16 . This could be explain by the fact that men usually travel for work particularly in professions of truck drivers, day working, and due to migrant agricultural works which keeps them away from their home likewise their medication 17 .
This study showed that ambulatory functional status decreased the hazard of loss to follow up by 80.3% as compared to those participants whose status was working (AHR=0.1967, 95% CI 0.049-0.794). Similar study done in southern Ethiopia support this study 11 . The possible justification for this could be due to their routine duety in the working group that could affect negatively their adharence or follow up while it could creat a better condition for those who were ambulatory to attend strictly their treatment.
In this study, those who have good adherence decreased the hazard of loss to follow up by 55.8 % as compared to those having poor adherence. A similar finding was reported by a study conducted in Nigeria 18 . Our findings highlight the need for strengthening of treatment adherence by counselors and support groups to minimize LTFU and this could be an indication of the integrity of better adherence and reduced LTFU that may probably work for the synergy of better health.
Age was not a significant risk factor of time loss to follow up in this study. On contrary to this, studies done in south Africa 19 , Nigeria 18 and southern Ethiopia 11 showed that the younger age was significantly related with higher level of loss to follow up. The contradiction of these studies could be due to the variation in age distribution of those studies 11, 18, 19 when comared to the current study .
In this study, CD4 count was not an independent predictor of time to LTFU. However, other studies done in India 6 and southern Ethiopia 20 showed that the lower baseline CD4 cell count was risk factor for LTFU. On the other hand studies conducted in SSA 7 and Ethiopia rural hospital 14 showed that higher CD4 cell count increased the risk of LTFU. The contradiction in these studies may be due to the difference in confounding variables that were not controlled by the respective studies as it could affect the true effect of CD4 count on LTFU.
In the current study, taking drug types of 2a, 2e and 2g reduced the hazard of LTFU when compared with those who took drug type 2k. This disparity among drugs with regard to the status of LTFU might be associated with the difference in the effectiveness of drugs in improving health which could subject itself to further research.
Limitation
This study included only adults beyond age 15 who were on ART; and this group of particpants might not represents individuals whose age was less than 15.The other limitation of the current study is that the possible outcomes of LTFU patients might not have been accurately captured as patients who were classified as LTFU might have actually died or been cared for in other facilities.
CONCLUSION
The incidence of LTFU in Amhara region hospitals was low. Loss to follow up was negatively associated with female gender, ambulatory baseline functional status, adherence, and second line drug types of 2a, 2e, and 2g. Close follow up is recommended to minimize LTFU and improve treatment outcomes of adults on ART with due emphasis for males with working functional status and poor adherence level. We also recommend further research on the effect of drug types by acertaining whether the reduction in LTFU for patients who took drug types of 2a, 2e, and 2g is associaed with improved or worsened health outcomes by trafcking closely lost patients.
